Semaglutide improves heart health and reduces weight in obese patients, but with side effects
Study shows that semaglutide not only aids in weight loss but also slashes heart failure risk by 76% in overweight ...
Tag: Agonist
GLP-1 receptor agonists show promise in treating substance use disorders
A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due ...
AlphaFold accelerates discovery of potential antipsychotic drugs by outperforming traditional methods
In a recent study published in the journal Science Advances, researchers in Sweden conducted virtual screens of over 16 million ...
Semaglutide may reduce smoking risks for diabetes patients
In a recent study published in the journal Annals of Internal Medicine, a team of researchers from the National Institutes ...
Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity
In a recent study published in Scientific Reports, researchers evaluated the impact of semaglutide and tirzepatide medications on alcohol consumption ...
Oral semaglutide outperforms other medications in type 2 diabetes treatment, significantly reducing HbA1c and body weight
A study analyzing the PIONEER trial data claims that orally administered semaglutide is highly effective in reducing glycated hemoglobin (HbA1c) ...
Researchers present a new strategy for self-adjuvanting vaccine development
This new article publication from Acta Pharmaceutica Sinica B, discusses a fully synthetic Tn-based three-component cancer vaccine using covalently linked ...
Scientists identify papain-like protease inhibitor against COVID-19
In a recent study posted to the bioRxiv* preprint server, researchers identified a papain-like protease inhibitor for treating severe acute ...
Scientists explore SARS-CoV-2 spike protein and platelet-activating factor
In a recent study published in the IUBMB journal, researchers assessed the association between platelet-activating factor (PAF) and severe acute ...
